Last updated: September 6, 2026
Capoten is the original brand of captopril, an angiotensin-converting enzyme inhibitor approved by the FDA in 1981. Its commercial value has shifted from branded innovation to low-cost generic supply. Brand-level revenue is no longer separately disclosed, and current sales are fragmented among generic manufacturers. Capoten has no meaningful U.S. exclusivity position, no active biosimilar issue, and limited commercial protection from patents.
What is Capoten and how is captopril used?
Capoten contains captopril, an oral ACE inhibitor used to treat hypertension, congestive heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy in selected patients. The FDA-approved product is available in tablet strengths including 12.5 mg, 25 mg, 50 mg, and 100 mg, with dosing generally divided two or three times daily because of captopril’s relatively short half-life.[1]
Captopril was developed by Squibb, now part of Bristol-Myers Squibb. It was derived from research into peptides associated with the venom of the Brazilian pit viper and became the first commercially approved ACE inhibitor.[2]
Capoten product profile
| Attribute |
Capoten |
| Active ingredient |
Captopril |
| Drug class |
ACE inhibitor |
| Original developer |
E. R. Squibb & Sons |
| FDA approval |
1981 |
| Primary indications |
Hypertension, heart failure, post-myocardial-infarction left ventricular dysfunction, diabetic nephropathy |
| U.S. dosage forms |
Immediate-release tablets |
| Current commercial status |
Mature branded product with generic competition |
| Biosimilar exposure |
None |
| Main competitors |
Lisinopril, enalapril, ramipril, benazepril, losartan and other antihypertensive drugs |
When did Capoten lose market exclusivity?
Capoten lost meaningful U.S. market exclusivity in the early 1990s after FDA approval of generic captopril products. The original Capoten patent estate has long expired. Generic captopril is approved under abbreviated new drug applications, allowing manufacturers to rely on the reference product’s safety and efficacy findings rather than repeat the full clinical program.[3]
The commercial transition followed the standard lifecycle for an early small-molecule drug:
- FDA approval in 1981.
- Commercial growth during the 1980s as the first ACE inhibitor.
- Expansion of ACE-inhibitor competition through enalapril and lisinopril.
- Generic entry in the early 1990s.
- Progressive reduction in branded pricing power.
- Ongoing low-cost generic use in selected patients.
Capoten patent expiration
Publicly available patent records do not support a current enforceable U.S. patent barrier for the core captopril molecule or the original Capoten product. The relevant patent protections expired decades ago. Any remaining patents that could appear in global records would generally concern manufacturing processes, formulations, combinations, or jurisdiction-specific rights rather than the basic U.S. product monopoly.
| Protection category |
Current commercial position |
| Captopril composition of matter |
Expired |
| Original Capoten product patents |
Expired |
| Core hypertension indication |
Unprotected by active U.S. exclusivity |
| Immediate-release tablet |
Generic competition |
| Manufacturing process patents |
Potentially relevant in isolated jurisdictions, but not a broad U.S. market barrier |
| Regulatory exclusivity |
Expired |
| Biosimilar exclusivity |
Not applicable |
What is the FDA regulatory status of Capoten?
Capoten was approved through the FDA’s new drug application pathway and is an established small-molecule product. Generic captopril products are approved through the ANDA pathway. Capoten does not have biologic status and is not subject to the Biologics Price Competition and Innovation Act.
The FDA Orange Book historically listed Capoten as the reference product for captopril tablets. Current market availability may vary by strength, manufacturer, distributor and pharmacy channel. Orange Book listings are relevant to regulatory substitution and reference-product status, but they do not restore market exclusivity after patent and regulatory protections expire.[3]
What is the Orange Book status of Capoten?
The commercial significance of the Orange Book listing is limited. Generic captopril products can be approved as therapeutically equivalent products when they satisfy FDA requirements. The listing does not prevent substitution by approved generic captopril tablets.
Capoten is also not materially exposed to Paragraph IV litigation today. Paragraph IV certifications are most commercially significant while listed patents remain unexpired. Because the core Capoten patents are long expired, the principal generic-entry disputes have already passed.
How many patents cover Capoten today?
No active patent portfolio appears to provide broad U.S. protection for Capoten or captopril tablets. The patent estate should be characterized as expired and commercially weak for the branded product.
What patents protected Capoten historically?
Historical protection likely covered the captopril compound, pharmaceutical compositions and related therapeutic uses. The key commercial asset was the active molecule rather than a complex delivery technology. Captopril is a conventional immediate-release small molecule, which limits the ability of later formulation patents to recreate the original market position.
Potential patent categories include:
- Captopril composition patents.
- Salt, crystal or formulation patents.
- Tablet manufacturing claims.
- Combination therapy claims.
- Treatment claims for hypertension, heart failure and diabetic nephropathy.
- Process patents for chemical synthesis.
These categories do not create a present-day monopoly over standard captopril tablets in the United States.
What drove Capoten’s market decline?
Capoten’s decline resulted from patent expiry, therapeutic substitution and product limitations.
Generic price erosion
Generic captopril is inexpensive because multiple manufacturers can supply the molecule and the product has low development risk. Pharmacy benefit managers, hospitals and public health systems generally have limited incentives to pay a premium for the Capoten brand when therapeutically equivalent generic tablets are available.
Competition from newer ACE inhibitors
Captopril was followed by longer-acting ACE inhibitors, particularly enalapril and lisinopril. Once-daily dosing and broader prescribing familiarity supported the shift away from captopril.
| Drug |
Commercial advantage over captopril |
| Captopril |
First approved ACE inhibitor; low generic cost |
| Enalapril |
Longer duration; strong heart-failure adoption |
| Lisinopril |
Once-daily dosing; broad hypertension use; extensive generic supply |
| Ramipril |
Cardiovascular-risk positioning in several markets |
| Benazepril |
Established hypertension product, often used in combination |
| Losartan |
Alternative mechanism for patients who cannot tolerate ACE inhibitors |
Captopril retains clinical utility, particularly where low acquisition cost matters or where clinicians prefer a short-acting ACE inhibitor. Its dosing frequency and adverse-effect profile have constrained broader use.
Therapeutic substitution
Captopril competes with both other ACE inhibitors and angiotensin receptor blockers. ARBs are often selected when cough or angioedema risk makes ACE-inhibitor therapy less suitable. Calcium-channel blockers, thiazide diuretics and fixed-dose combination products further reduce the addressable market for stand-alone captopril.
What is Capoten’s current market size and revenue exposure?
A standalone current Capoten revenue figure is not publicly disclosed. Bristol-Myers Squibb does not report Capoten as a material separately identified product in its current financial reporting, and the U.S. market is primarily generic.
The economically relevant market is generic captopril, not branded Capoten. Revenue is distributed across manufacturers and channels, with pricing determined by generic competition, procurement contracts and supply conditions.
Financial trajectory
| Period |
Commercial and financial profile |
| 1981-1985 |
Launch and early adoption as the first approved ACE inhibitor |
| Late 1980s |
Strong branded growth, supported by hypertension and heart-failure demand |
| Early 1990s |
Generic entry and rapid reduction in brand pricing power |
| 1990s-2000s |
Declining branded revenue as lisinopril and enalapril expanded |
| 2010s |
Mature generic market with low unit prices |
| 2020s |
Limited brand relevance; value concentrated in generic volume and supply contracts |
Capoten’s financial trajectory is therefore a classic post-exclusivity curve: high value during innovation and protected commercialization, followed by rapid erosion after generic entry and eventual marginal brand contribution.
Which companies manufacture or market captopril?
Generic captopril has historically been supplied by multiple manufacturers, including major generic companies and regional pharmaceutical producers. Product availability changes as companies discontinue products, transfer approvals or adjust manufacturing portfolios.
The relevant competitive factors are:
- FDA approval and therapeutic equivalence.
- Reliable active pharmaceutical ingredient supply.
- Manufacturing cost.
- Contract access with wholesalers and group purchasing organizations.
- Ability to maintain supply across tablet strengths.
- Manufacturing compliance and inspection history.
- Pricing discipline in a mature generic market.
Bristol-Myers Squibb retains historical association with Capoten, but the branded product no longer has the commercial leverage associated with an in-patent cardiovascular medicine.
What manufacturing and intellectual-property barriers affect captopril?
Manufacturing barriers are moderate rather than high. Captopril is a small molecule with established synthetic routes and a long history of commercial production. The main operational risks involve:
- Active pharmaceutical ingredient sourcing.
- Impurity control.
- Stability and packaging.
- Compliance with current good manufacturing practice.
- Reliable production of multiple low-volume strengths.
- Supply economics where prices are compressed.
Captopril contains a sulfhydryl group, which contributes to chemical and clinical characteristics that manufacturers must control through formulation and stability testing. These technical requirements do not create a meaningful exclusivity barrier, but they can affect product quality and supply continuity.
Are formulation patents important for Capoten?
Formulation patents have limited current value for standard Capoten tablets. The product is an immediate-release oral tablet without a complex delivery system, device, depot formulation or biologic manufacturing process.
A manufacturer could seek protection for a new formulation, fixed-dose combination or modified-release product, but such claims would protect the new product only if they satisfy novelty, nonobviousness and enablement requirements. They would not restore exclusivity for standard captopril tablets.
What patent litigation and settlement agreements affect Capoten?
No current major U.S. patent litigation appears to constrain generic captopril access. Historical generic challenges would have centered on expired Capoten patents and Paragraph IV certifications. Any historical settlements would have limited present commercial relevance because the underlying exclusivity periods have ended.
There is no current litigation pattern comparable to branded drugs with active Orange Book patents, authorized-generic strategies or delayed-entry settlements. The absence of meaningful litigation is itself an indicator of the product’s mature lifecycle.
What generic launch scenarios exist for Capoten?
Generic launch risk is effectively realized rather than prospective. Generic captopril has already entered the U.S. market, so the relevant scenarios concern supply and pricing:
Base case
Generic manufacturers continue supplying captopril at low prices. Capoten remains clinically recognized but has little branded pricing power.
Downside for manufacturers
Additional suppliers or aggressive contracting produce further price compression. Low-margin products may be discontinued if manufacturing, compliance or distribution costs rise.
Supply-constrained scenario
A manufacturer disruption could produce temporary shortages or price increases. Such an event would reflect supply concentration rather than patent protection.
Reformulation scenario
A company could pursue a differentiated captopril formulation or combination product. Commercial success would depend on clinical convenience, reimbursement and competition from established once-daily ACE inhibitors.
How does Capoten compare with lisinopril and enalapril?
Capoten is commercially weaker than lisinopril and enalapril because it is shorter-acting and often requires multiple daily doses. All three products face generic competition, but lisinopril has stronger continuing market presence in routine hypertension treatment.
| Factor |
Capoten |
Lisinopril |
Enalapril |
| Active ingredient |
Captopril |
Lisinopril |
Enalapril |
| Generic status |
Mature generic |
Mature generic |
Mature generic |
| Dosing convenience |
Often two or three times daily |
Commonly once daily |
Once or twice daily |
| Brand value |
Minimal |
Minimal |
Minimal |
| Patent risk |
Expired |
Expired |
Expired |
| Biosimilar risk |
None |
None |
None |
| Main commercial role |
Low-cost, established ACE inhibitor |
Broad generic hypertension use |
Hypertension and heart failure |
| Differentiation potential |
Limited |
Limited |
Limited |
What is the competitive outlook for Capoten?
Capoten is a mature, low-growth pharmaceutical asset. Volume demand is supported by the global prevalence of hypertension and cardiovascular disease, but the product has limited ability to capture value because of generic competition and therapeutic substitution.
The strongest commercial opportunities are outside the traditional branded model:
- Efficient generic manufacturing.
- Reliable supply in underserved markets.
- Government and hospital tenders.
- Fixed-dose combinations.
- Regional distribution.
- Cost-focused cardiovascular portfolios.
The main risks are low margins, declining brand recognition, supplier consolidation and replacement by once-daily ACE inhibitors or ARBs.
Key Takeaways
- Capoten is the original brand of captopril and was FDA-approved in 1981.
- Its core patents and regulatory exclusivity expired decades ago.
- Generic captopril, not branded Capoten, represents the current commercial market.
- Bristol-Myers Squibb does not publicly disclose material standalone Capoten revenue.
- There is no meaningful current U.S. Paragraph IV or Orange Book patent barrier.
- Biosimilar risk is irrelevant because captopril is a small molecule.
- Lisinopril and enalapril have stronger commercial positions because of dosing convenience and established generic use.
- Current value lies in manufacturing efficiency, supply reliability and low-cost distribution.
- Capoten has little ability to support premium pricing or brand-led growth.
FAQs About Capoten Market Dynamics and Patent Status
Is Capoten still available in the United States?
Generic captopril remains the relevant U.S. product. Availability of the branded Capoten product can vary by strength, distributor and manufacturer status.
Does Capoten have any remaining patent protection?
No broad active U.S. patent protection is expected to cover standard captopril tablets. The original molecule and product protections expired long ago.
Can a generic manufacturer launch captopril without a Paragraph IV challenge?
Yes. Once relevant listed patents expire, an ANDA applicant can use an appropriate certification pathway without relying on a Paragraph IV challenge to block unexpired patents.
Is captopril a biologic or subject to biosimilar competition?
No. Captopril is a chemically synthesized small molecule approved under the conventional drug framework. Generic substitution, not biosimilar competition, determines its market structure.
Could a new captopril formulation obtain market exclusivity?
A genuinely novel formulation or combination could qualify for patent protection or regulatory exclusivity if it satisfies applicable legal standards. That protection would apply to the new product, not to standard Capoten tablets.
References
- U.S. Food and Drug Administration. (1981). Capoten (captopril) prescribing information.
- Cushman, D. W., & Ondetti, M. A. (1991). History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension, 17(4), 589-592.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Bristol-Myers Squibb Company. (2024). Annual report.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs.
